These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27586803)

  • 1. From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis.
    Tyrsin D; Chuvpilo S; Matskevich A; Nemenov D; Römer PS; Tabares P; Hünig T
    Clin Exp Rheumatol; 2016; 34(4 Suppl 98):45-8. PubMed ID: 27586803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08.
    Tabares P; Berr S; Römer PS; Chuvpilo S; Matskevich AA; Tyrsin D; Fedotov Y; Einsele H; Tony HP; Hünig T
    Eur J Immunol; 2014 Apr; 44(4):1225-36. PubMed ID: 24374661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account.
    Hünig T
    FEBS J; 2016 Sep; 283(18):3325-34. PubMed ID: 27191544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice.
    Gogishvili T; Langenhorst D; Lühder F; Elias F; Elflein K; Dennehy KM; Gold R; Hünig T
    PLoS One; 2009; 4(2):e4643. PubMed ID: 19247496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD28 superagonists: what makes the difference in humans?
    Schraven B; Kalinke U
    Immunity; 2008 May; 28(5):591-5. PubMed ID: 18482560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies.
    Waibler Z; Sender LY; Merten C; Hartig R; Kliche S; Gunzer M; Reichardt P; Kalinke U; Schraven B
    PLoS One; 2008 Mar; 3(3):e1708. PubMed ID: 18320029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-Recognition Sensitizes Mouse and Human Regulatory T Cells to Low-Dose CD28 Superagonist Stimulation.
    Langenhorst D; Tabares P; Gulde T; Becklund BR; Berr S; Surh CD; Beyersdorf N; Hünig T
    Front Immunol; 2017; 8():1985. PubMed ID: 29441059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD28 superagonists put a break on autoimmunity by preferentially activating CD4+CD25+ regulatory T cells.
    Beyersdorf N; Hanke T; Kerkau T; Hünig T
    Autoimmun Rev; 2006 Jan; 5(1):40-5. PubMed ID: 16338210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412.
    Römer PS; Berr S; Avota E; Na SY; Battaglia M; ten Berge I; Einsele H; Hünig T
    Blood; 2011 Dec; 118(26):6772-82. PubMed ID: 21931118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist.
    Thaventhiran T; Alhumeed N; Yeang HX; Sethu S; Downey JS; Alghanem AF; Olayanju A; Smith EL; Cross MJ; Webb SD; Williams DP; Bristow A; Ball C; Stebbings R; Sathish JG
    MAbs; 2014; 6(5):1290-9. PubMed ID: 25517314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.
    Eastwood D; Findlay L; Poole S; Bird C; Wadhwa M; Moore M; Burns C; Thorpe R; Stebbings R
    Br J Pharmacol; 2010 Oct; 161(3):512-26. PubMed ID: 20880392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipilimumab (Yervoy) and the TGN1412 catastrophe.
    Bakacs T; Mehrishi JN; Moss RW
    Immunobiology; 2012 Jun; 217(6):583-9. PubMed ID: 21821307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Some aspects of the recombinantly expressed humanised superagonist anti-CD28 mAb, TGN1412 trial catastrophe lessons to safeguard mAbs and vaccine trials.
    Mehrishi JN; Szabó M; Bakács T
    Vaccine; 2007 May; 25(18):3517-23. PubMed ID: 17397974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies.
    Hünig T
    Adv Immunol; 2007; 95():111-48. PubMed ID: 17869612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD28 signals the differential control of regulatory T cells and effector T cells.
    Mikami N; Sakaguchi S
    Eur J Immunol; 2014 Apr; 44(4):955-7. PubMed ID: 24652756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases.
    Beyersdorf N; Hanke T; Kerkau T; Hünig T
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv91-5. PubMed ID: 16239397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD28/CTLA-4/B7 costimulatory pathway blockade affects regulatory T-cell function in autoimmunity.
    Vogel I; Kasran A; Cremer J; Kim YJ; Boon L; Van Gool SW; Ceuppens JL
    Eur J Immunol; 2015 Jun; 45(6):1832-41. PubMed ID: 25727069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo activation of Treg cells with a CD28 superagonist prevents and ameliorates chronic destructive arthritis in mice.
    Win SJ; Kühl AA; Sparwasser T; Hünig T; Kamradt T
    Eur J Immunol; 2016 May; 46(5):1193-202. PubMed ID: 26711629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD28 superagonists: mode of action and therapeutic potential.
    Hünig T; Dennehy K
    Immunol Lett; 2005 Aug; 100(1):21-8. PubMed ID: 16054703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. After TGN1412: recent developments in cytokine release assays.
    Stebbings R; Eastwood D; Poole S; Thorpe R
    J Immunotoxicol; 2013; 10(1):75-82. PubMed ID: 22967038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.